Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Mauro Maccarroneab , Rafael Maldonadoc, Miguel Casasdef, Thomas Henzeg & Diego CentonzehDepartment of Medicine, Campus Bio-Medico University of Rome , Rome, Italy Laboratory of Lipid Neurochemistry, European Center for Brain Research/IRCCS Santa Lucia Foundation , Rome, Italy Laboratori de Neurofarmacologia, Departament de Ciències Experimentals i de la Salut (CEXS), Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra , Barcelona, Spain Servicio de Psiquiatría, Hospital Universitari Vall d’Hebron , Barcelona, Spain Departamento de Psiquiatría y Medicina Legal, Universitat Autònoma de Barcelona , Barcelona, Spain CIBERSAM , Barcelona, Spain Passauer Wolf Reha-Zentrum Nittenau , Nittenau, Germany Multiple Sclerosis Clinical and Research Center, Tor Vergata University, Rome & Unit of Neurology, IRCCS Istituto Neurologico Mediterraneo Neuromed , Pozzilli, Italy CONTACT Mauro Maccarrone m.maccarrone@unicampus.it Department of Medicine, Campus Bio-Medico University of Rome , Via Alvaro del Portillo 21, 00128 Rome, Italy, ABSTRACT Introduction: The complexity of the endocannabinoid (eCB) system is becoming better understood and new drivers of eCB signaling are emerging. Modulation of the activities of the eCB system can be therapeutic in a number of diseases. Research into the eCB system has been paralleled by the development of agents that interact with cannabinoid receptors. In this regard it should be remembered that herbal cannabis contains a myriad of active ingredients, and the individual cannabinoids have quite distinct biological activities requiring independent studies. Areas covered: This article reviews the most important current data involving the eCB system in relation to human diseases, to reflect the present (based mainly on the most used prescription cannabinoid medicine, THC/CBD oromucosal spray) and potential future uses of cannabinoid-based therapy. Expert commentary: From the different therapeutic possibilities, THC/CBD oromucosal spray has been in clinical use for approximately five years in numerous countries world-wide for the management of multiple sclerosis (MS)-related moderate to severe resistant spasticity. Clinical trials have confirmed its efficacy and tolerability. Other diseases in which different cannabinoids are currently being investigated include various pain states, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and epilepsy. The continued characterization of individual cannabinoids in different diseases remains important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Cannabinoids for Medical Use: A Systematic Review and Meta-analysis
Whiting, P. F., Wolff, R. F., Deshpande, S., Di Nisio, M., Duffy, S., Hernandez, A. V., Keurentjes, J. C., Lang, S., Misso, K., Ryder, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.6358 · Cited by 2,169 · cited 3×
“tions, and non-randomized clinical studies with at least 25 patients, published in the last 40 years (1975–2015, [36]).”
BackgroundTaming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.
Russo, E. B. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01238.x · Cited by 1,535
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
De Petrocellis, L., Ligresti, A., Moriello, A. S., Allarà, M., Bisogno, T., Petrosino, S., Stott, C. G., & Di Marzo, V. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01166.x · Cited by 946
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Devinsky, O., Marsh, E., Friedman, D., Thiele, E., Laux, L., Sullivan, J., Miller, I., Flamini, R., Wilfong, A., Filloux, F., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00379-8 · Cited by 900
Zajicek, J., Fox, P., Sanders, H., Wright, D., Vickery, J., Nunn, A., & Thompson, A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14738-1 · Cited by 827 · cited 1×
“Nevertheless, many patients have reported positive effects on overall mobility and on subjective impression of pain reduction [58].”
BackgroundWade, D. T., Makela, P., Robson, P., House, H., & Bateman, C. (2004) · Multiple Sclerosis Journal · doi:10.1191/1352458504ms1082oa · Cited by 589 · cited 1×
“Findings from two phase III pivotal studies [70,71] and a study by Wade and colleagues [72] were combined in a meta-analysis [59], and adverse events (AEs) were reported by 79.”
MethodIbrahim, M. M., Porreca, F., Lai, J., Albrecht, P. J., Rice, F. L., Khodorova, A., Davar, G., Makriyannis, A., Vanderah, T. W., Mata, H. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409888102 · Cited by 521
The Endocannabinoid System and Pain
Guindon, J., & Hohmann, A. (2009) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152709789824660 · Cited by 476
Novotna, A., Mares, J., Ratcliffe, S., Novakova, I., Vachova, M., Zapletalova, O., Gasperini, C., Pozzilli, C., Cefaro, L., Comi, G., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.03328.x · Cited by 475
Portenoy, R. K., Ganae-Motan, E. D., Allende, S., Yanagihara, R., Shaiova, L., Weinstein, S., McQuade, R., Wright, S., & Fallon, M. T. (2012) · The Journal of Pain · doi:10.1016/j.jpain.2012.01.003 · Cited by 420 · cited 1×
“reported to be more effective than preparations containing THC in one clinical trial [37] and no apparent differences in two addi-”
BackgroundCosta, B., Trovato, A. E., Comelli, F., Giagnoni, G., & Colleoni, M. (2007) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.11.006 · Cited by 395
Early phytocannabinoid chemistry to endocannabinoids and beyond
Mechoulam, R., Hanuš, L. O., Pertwee, R., & Howlett, A. C. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3811 · Cited by 393 · cited 2×
“>400 other substances that might interact, alone or in combination, in the human body with the possibility of producing physiological/medical effects [1,2].”
BackgroundFischedick, J. T., Hazekamp, A., Erkelens, T., Choi, Y. H., & Verpoorte, R. (2010) · Phytochemistry · doi:10.1016/j.phytochem.2010.10.001 · Cited by 325 · cited 1×
“indica cannabinoids have different chemical fingerprints and we now refer to them as ‘chemovars’ rather than ‘cultivars’ [3].”
BackgroundEsposito, G., Scuderi, C., Savani, C., Steardo, L., De Filippis, D., Cottone, P., Iuvone, T., Cuomo, V, & Steardo, L. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707337 · Cited by 308
Cannabinoids as Pharmacotherapies for Neuropathic Pain: From the Bench to the Bedside
Rahn, E. J., & Hohmann, A. G. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2009.08.002 · Cited by 305 · cited 2×
“The effectiveness of cannabinoid compounds on neuropathic pain has been shown in multiple animal models including constriction injury, sciatic and spinal nerve ligation, as well as diabetic, chemotherapy, lysolecithin, and viral-induced neuropathy [127].”
BackgroundCannabis use and educational achievement: Findings from three Australasian cohort studies
Horwood, L. J., Fergusson, D. M., Hayatbakhsh, M. R., Najman, J. M., Coffey, C., Patton, G. C., Silins, E., & Hutchinson, D. M. (2010) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2010.03.008 · Cited by 302 · cited 1×
“sativa derivatives among adolescents and young adults is a cause for concern given the association between continued use and academic failure [14], problem behaviors [15], and traffic acci-”
BackgroundLangford, R. M., Mares, J., Novotna, A., Vachova, M., Novakova, I., Notcutt, W., & Ratcliffe, S. (2013) · Journal of Neurology · doi:10.1007/s00415-012-6739-4 · Cited by 298 · cited 1×
“ment plus a 4-week double-blind randomized withdrawal phase and there was an increased time to treatment failure in THC/CBD patients compared to placebo [68].”
MethodProgramming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies
Maccarrone, M., Guzmán, M., Mackie, K., Doherty, P., & Harkany, T. (2014) · Nature Reviews Neuroscience · doi:10.1038/nrn3846 · Cited by 298 · cited 2×
“proliferator-activated receptors (PPARs) [5].”
BackgroundSelf-citationCollin, C., Ehler, E., Waberzinek, G., Alsindi, Z., Davies, P., Powell, K., Notcutt, W., O'Leary, C., Ratcliffe, S., Nováková, I., et al. (2010) · Neurological Research · doi:10.1179/016164109x12590518685660 · Cited by 283 · cited 1×
“Findings from two phase III pivotal studies [70,71] and a study by Wade and colleagues [72] were combined in a meta-analysis [59], and adverse events (AEs) were reported by 79.”
MethodChen, C.-Y., O’Brien, M. S., & Anthony, J. C. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.11.014 · Cited by 260
Genetic predisposition to schizophrenia associated with increased use of cannabis
Power, R. A., Verweij, K. J. H., Zuhair, M., Montgomery, G. W., Henders, A. K., Heath, A. C., Madden, P. A. F., Medland, S. E., Wray, N. R., & Martin, N. G. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.51 · Cited by 196
Racz, I., Nadal, X., Alferink, J., Baños, J. E., Rehnelt, J., Martín, M., Pintado, B., Gutierrez-Adan, A., Sanguino, E., Manzanares, J., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3400-08.2008 · Cited by 195
Self-citationPharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice
Aso, E., Sánchez-Pla, A., Vegas-Lozano, E., Maldonado, R., & Ferrer, I. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-141014 · Cited by 154 · cited 1×
“Behavioral improvement was associated with reduced astrogliosis, microgliosis, levels of inflammatory-relatedmolecules, and a decrease in soluble amyloid-β levels, the most toxic form of amyloid-β [99].”
BackgroundThe potential therapeutic effects of THC on Alzheimer’s disease
Cao, C., Li, Y., Liu, H., Bai, G., Mayl, J., Lin, X., Sutherland, K., Nabar, N., & Cai, J. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-140093 · Cited by 121
Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists
Grenald, S. A., Young, M. A., Wang, Y., Ossipov, M. H., Ibrahim, M. M., Largent-Milnes, T. M., & Vanderah, T. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.12.008 · Cited by 97
Nadal, X., La Porta, C., Andreea Bura, S., & Maldonado, R. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.01.077 · Cited by 76 · cited 3×
“At the supraspinal level, CB1 stimulation inhibits ascending pain transmission, mainly at the thalamus level, improves the emotional pain component acting in the limbic and cortical areas, and activates the descending inhibitory pathway at the level of the periaqueductal gray matter and nucleus raphe magnus [104,106].”
BackgroundSelf-citationCannabinoids: The separation of central from peripheral effects on a structural basis
Evans, F. (1991) · Planta Medica · doi:10.1055/s-2006-960231 · Cited by 76
La Porta, C., Bura, S. A., Aracil-Fernández, A., Manzanares, J., & Maldonado, R. (2013) · Pain · doi:10.1016/j.pain.2012.10.009 · Cited by 75 · cited 2×
“CB2 receptors have also been reported to play a major role in the development of the nociceptive manifestations of osteoarthritis pain [128], whereas CB1 has a predominant role in the affective component of this chronic pain condition [129].”
BackgroundSelf-citationGiordano, G. N., Ohlsson, H., Sundquist, K., Sundquist, J., & Kendler, K. S. (2015) · Psychological Medicine · doi:10.1017/s0033291714001524 · Cited by 74
Neurobehavioral actions of cannabichromene and interactions with Δ9-tetrahydrocannabinol
Davis, W. M., & Hatoum, N. S. (1983) · General Pharmacology: The Vascular System · doi:10.1016/0306-3623(83)90004-6 · Cited by 67
Cited by
Safety, efficacy, and mechanisms of action of cannabinoids in neurological disorders
Friedman, D., French, J. A., & Maccarrone, M. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30032-8 · Cited by 203
Self-citationGoods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Maccarrone, M., Di Marzo, V., Gertsch, J., Grether, U., Howlett, A. C., Hua, T., Makriyannis, A., Piomelli, D., Ueda, N., & van der Stelt, M. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000600 · Cited by 183
Self-citationChiurchiù, V., van der Stelt, M., Centonze, D., & Maccarrone, M. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.10.007 · Cited by 140
“of the published studies is generally weak, in clinical conditions other than MS-associated spasticity and neuropathic pain, and in the case of preparations other than nabiximols (Koppel et al., 2014; Maccarrone et al., 2017).”
InfluentialSelf-citationCannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Alves, P., Amaral, C., Teixeira, N., & Correia-da-Silva, G. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104822 · Cited by 135
Oral manifestations of illicit drug use
Teoh, L., Moses, G., & McCullough, M. (2019) · Australian Dental Journal · doi:10.1111/adj.12709 · Cited by 69
Metadata
- Authors
- Maccarrone, M., Maldonado, R., Casas, M., Henze, T., & Centonze, D.
- Venue
- Expert Review of Clinical Pharmacology
- Publisher
- Informa UK Limited
- Published
- 2017-02-28
- Volume
- 10
- Issue
- 4
- Pages
- 443-455
- ISSN
- 1751-2433 (ISSN-L)
- 1751-2441
- OpenAlex
- W2586473686
- Cited by
- 80
- References
- 34
- FWCI
- 8.01
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.